These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24816187)

  • 1. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
    Moisan F; Francisco EB; Brozovic A; Duran GE; Wang YC; Chaturvedi S; Seetharam S; Snyder LA; Doshi P; Sikic BI
    Mol Oncol; 2014 Oct; 8(7):1231-9. PubMed ID: 24816187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
    Brozovic A; Duran GE; Wang YC; Francisco EB; Sikic BI
    Mol Oncol; 2015 Oct; 9(8):1678-93. PubMed ID: 26025631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells
    Kuittinen T; Rovio P; Luukkaala T; Laurila M; Grénman S; Kallioniemi A; Mäenpää J
    Anticancer Res; 2020 Jun; 40(6):3129-3138. PubMed ID: 32487607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
    Stamelos VA; Robinson E; Redman CW; Richardson A
    Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer.
    Geller MA; Bui-Nguyen TM; Rogers LM; Ramakrishnan S
    Int J Gynecol Cancer; 2010 Aug; 20(6):918-25. PubMed ID: 20683396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
    Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
    Gynecol Oncol; 2014 Feb; 132(2):455-61. PubMed ID: 24378876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.
    Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Tangtiang K; Piyawang W; Bhamarapravatana K
    J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S121-5. PubMed ID: 26387399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
    Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
    Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.
    Larbi E; Madhuri K; Essapen S; Butler-Manuel S; Tailor A; Michael A
    Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):75. PubMed ID: 23146339
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.
    Nagao S; Fujiwara K; Ohishi R; Nakanishi Y; Iwasa N; Shimizu M; Goto T; Shimoya K
    Int J Gynecol Cancer; 2008; 18(6):1210-4. PubMed ID: 18284454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
    PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA; Hartmann LC
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
    PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
    Nakamura Y; Kamei T; Shinagawa M; Sakamoto Y; Miwa I
    J Obstet Gynaecol Res; 2015 May; 41(5):809-12. PubMed ID: 25511544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle.
    Samykutty A; Grizzle WE; Fouts BL; McNally MW; Chuong P; Thomas A; Chiba A; Otali D; Woloszynska A; Said N; Frederick PJ; Jasinski J; Liu J; McNally LR
    Biomaterials; 2018 Nov; 182():114-126. PubMed ID: 30118979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carboplatin in cancer of the ovary].
    Pujade-Lauraine E; Guastalla JP; Vincent P
    Bull Cancer; 2000 Aug; 87 Spec No():40-7. PubMed ID: 11082722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.